CXCR4/CXCL12在肿瘤中的研究进展  

The Research Progress of CXCR4/CXCL12 in Tumors

作　　者：曹学良[1] 付鹏[2] 栾厦[1] 姜廷军[1] 赵长久[1] 

机构地区：[1]哈尔滨医科大学附属第四医院,黑龙江哈尔滨150001 [2]哈尔滨医科大学第一临床医学院,黑龙江哈尔滨150001

出　　处：《现代生物医学进展》2016年第3期577-579,514,共4页Progress in Modern Biomedicine

基　　金：黑龙江省青年科学基金项目(QC2011C052)

摘　　要：研究表明趋化因子及其受体在胚胎发育、干细胞迁移以及各种免疫反应中发挥重要作用,是许多生理及病理过程中细胞运动的重要因素。趋化因子受体CXCR4是一个由352个氨基酸构成的、7次跨膜的G蛋白偶联受体。趋化因子CXCL12为其特异性受体。研究发现,CXCR4/CXCL12在多种肿瘤中都有表达,在肿瘤的生长、血管生成、转移等方面发挥着重要作用。与正常组织相比,肿瘤组织及转移灶CXCR4高表达。因此,对CXCR4/CXCL12轴在肿瘤病生理中的作用机制进行进一步研究,很可能为肿瘤的治疗及对肿瘤转移的预防提供一个新的思路。我们现在就对其在肿瘤病生理中的作用做一综述。Previous studies show that chemokines and their receptors play important roles in embryonic development, stem cell trafficking and inflammatory reactions. It is the central factor in directing cell movement of many pathologic and physiologic processes.The chemokines and their receptors play multiple roles in tumor pathogenesis. CXCR4 is a 352 amino acid seven transmembrane rhodopsin-like G protein-coupled receptor. CXCL12 is the specific ligand for CXCR4. CXCR4/CXCL12 is widely expressed in tumor cells and has been demonstrated that it promotes tumor growth, enhances tumor angiogenesis, participates in tumor metastasis. Compared with normal tissue, primary tumor tissue and metastases express high level of CXCR4. So the CXCL12/CXCR4 pathway is an important target for the development of novel anti-cancer therapies. In this review, we consider the pathological nature and characteristics of the CXCL12/CXCR4 pathway in the tumor microenvironment. Strategies for therapeutically targeting the CXCL12/CXCR4 axis also are discussed.

关 键 词：趋化因子 CXCR4 CXCL12 肿瘤 

分 类 号：R730.2[医药卫生—肿瘤]